Summary

• 100% technical buy signals.
• 17 new highs and up 27.51% in the last month.
• 62.22% gain in the last year.

The Barchart Chart of the Day belongs to the Biomedical company Alkermes (Nasdaq: ALKS). I found the stock by using Barchart's powerful screening tools to find the stocks with the highest Weighted Alpha and technical buy signals. That resulted in a watch list of 37 stocks. After I sorted for the most frequent number of new highs in the last month, I used the Flipchart feature to review the charts for consistent prices appreciation. Since the Trend Spotter signaled a buy on 7/30 the stock gained 15.19%.

Alkermes plc, a biopharmaceutical company, researches, develops and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Barchart technical indicators:

• 100% technical buy signals
• 86.89+ Weighted Alpha
• 62.22% gain in the last year
• Trend Spotter buy signal
• Above its 20, 50 and 100 day moving averages
• 17 new highs and up 27.51% in the last month
• Relative Strength Index 75.46%
• Technical support level at 29.33
• Recently traded at 29.80 with a 50 day moving average of 25.74

Fundamental factors:

• Market Cap $4.77 billion
• P/E 138.52
• Revenue expected to grow 12.80% this year and another 8.60% next year
• Earnings estimated to increase 46.50% this year and another 77.80% next year
• Wall Street analysts issued 1 strong buy, 4 buy, and 7 hold recommendations on the stock
• The individua investors following the stock on Motley Fool voted 313 to 13 that the stock will beat the market, with the more experienced investors voting 68 to 3 for the same result
• 9,840 investors are monitoring the stock on Seeking Alpha